Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Why Clovis Oncology Inc. Shares Took Off

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Clovis Oncology  (NASDAQ: CLVS  ) are trading 14% higher today after the development-stage biotech announced the presentation of data at an upcoming American Society of Clinical Oncology (ASCO) meeting. Also driving today's gains was the news that AstraZeneca (NYSE: AZN  ) will also present data on a very similar drug at the same meeting.

So what: Clovis announced last night that it would present five abstracts on the progress in phase 1 and phase 2 studies of CO-1686, an oral targeted covalent inhibitor of the epidermal growth factor receptor (EGFR) to be used in treating non-small-cell lung cancer. AstraZeneca's development-stage cancer drug AZN9291 also aims to treat the same type of lung cancer, and its more detailed data revealed that 51% of the 177 patients involved in a study had their tumors shrink during treatment.

AZN9291 was granted "breakthrough therapy" status by the FDA to speed its arrival to the market, but some analysts have pointed out that Clovis' CO-1686 appears to be a safer treatment than AstraZeneca's drug, as AZN9291 appears to produce higher rates of adverse response.

Now what: AstraZeneca's own projections anticipate up to $3 billion in revenue from AZN9291, so a safer alternative could easily steal much of its thunder. Clovis has no real revenue to speak of yet, but if it can capture even half of that $3 billion market opportunity, it would pull in nearly enough revenue to drop to a price-to-sales ratio of less than one. AstraZeneca, in comparison, has a price-to-sales ratio of nearly 4, although it does have a broader range of drugs both on the market and in its pipeline.

Clovis' shares have experienced a lot of volatility since it doubled last year on positive CO-1686 data, and there's bound to be more in store before the company can move this exciting drug through its final trials. I'd be cautious here, but there may be enough reason for optimism to put a speculative toe in the water -- just make sure you understand what Clovis' and AstraZeneca's data really means first.

Invest in the next wave of health care innovation
The Economist compares this disruptive invention to the steam engine and the printing press. Business Insider says it's "the next trillion dollar industry." And the technology behind is poised to set off one of the most remarkable health care revolutions in decades. The Motley Fool's exclusive research presentation dives into this technology's true potential, and its ability to make life-changing medical solutions never thought possible. To learn how you can invest in this unbelievable new technology, click here now to see our free report.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2959941, ~/Articles/ArticleHandler.aspx, 9/1/2015 6:41:36 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Alex Planes

Alex Planes specializes in the deep analysis of tech, energy, and retail companies, with a particular focus on the ways new or proposed technologies can (and will) shape the future. He is also a dedicated student of financial and business history, often drawing on major events from the past to help readers better understand what's happening today and what might happen tomorrow.

Connect with Alex on LinkedIn or Twitter for more news and insight:

View Alex Planes's profile on LinkedIn

Today's Market

updated Moments ago Sponsored by:
DOW 16,058.35 -469.68 -2.84%
S&P 500 1,913.85 -58.33 -2.96%
NASD 4,636.11 -140.40 -2.94%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/1/2015 4:04 PM
AZN $30.69 Down -0.59 -1.89%
AstraZeneca plc (A… CAPS Rating: ****
CLVS $79.00 Up +1.14 +1.46%